Clinical Scorecard: Case Study: Transitioning from Chronic Infection to Disseminated Strongyloidiasis in a Patient with Corticosteroid-Induced Hyperinfection Syndrome
At a Glance
Category
Detail
Condition
Strongyloides stercoralis infection
Key Mechanisms
Corticosteroid-induced hyperinfection syndrome leading to disseminated strongyloidiasis
Target Population
Immunocompromised individuals, particularly those with a history of chronic strongyloidiasis
Care Setting
Clinical case management in a hospital setting
Key Highlights
Strongyloides stercoralis can cause life-threatening hyperinfection syndrome in immunocompromised patients.
Initial symptoms may mimic other conditions, complicating diagnosis.
Corticosteroid therapy can exacerbate strongyloidiasis, leading to severe complications.
Multi-site sampling is crucial for accurate diagnosis in disseminated cases.
Prompt discontinuation of immunosuppressive therapy and initiation of anthelmintic treatment are essential.
Guideline-Based Recommendations
Diagnosis
Consider screening for strongyloidiasis before initiating systemic corticosteroids in at-risk patients.
Utilize multi-site and repeated sampling for diagnosis in cases of suspected dissemination.
Management
Discontinue immunosuppressive therapy immediately upon diagnosis of strongyloidiasis.
Initiate anthelmintic treatment with albendazole or ivermectin.
Monitoring & Follow-up
Monitor for symptoms of hyperinfection syndrome and disseminated infection.
Regular follow-up to assess treatment response and symptom resolution.
Risks
Corticosteroid therapy can lead to rapid progression of strongyloidiasis.
Diagnostic delays can result in severe complications and increased mortality.
Patient & Prescribing Data
Elderly patients with a history of bronchial asthma and immunocompromised status.
Methylprednisolone and itraconazole were initially used but led to exacerbation; albendazole was effective post-discontinuation.
Clinical Best Practices
Maintain a high index of suspicion for strongyloidiasis in immunocompromised patients.
Educate patients about the risks associated with corticosteroid use in endemic areas.
Implement preventive screening strategies for strongyloidiasis in at-risk populations.
